Welcome to our dedicated page for Zura Bio SEC filings (Ticker: ZURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zura Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zura Bio's regulatory disclosures and financial reporting.
Zura Bio Limited furnished an updated corporate presentation dated July 1, 2026 for use at upcoming conferences and investor meetings. The presentation is provided as Exhibit 99.1 and is also available in the News & Events section of the company’s investor website.
The information is furnished under Item 7.01 of Form 8-K and is not deemed filed for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act, nor incorporated by reference into other SEC filings unless specifically referenced.
Zura Bio Ltd reports that officer Mathew Marlyn Teresa, VP and Principal Accounting Officer, holds 129,182 Class A ordinary shares, including 32,296 shares underlying restricted stock units that vest in full on May 18, 2027 if continuous service is maintained.
He also holds several employee share options over Class A ordinary shares, including 66,220 shares at an exercise price of $6.03, 81,150 shares at $1.20, 90,000 shares at $3.38, and additional tranches at a $0.00 exercise price, with expirations between 2032 and 2036. The option awards vest over time, with initial vesting dates on March 15, 2024, June 18, 2025, February 27, 2026 and April 1, 2027, subject to his continued service.
Zura Bio Ltd director Jennifer Jarrett received a grant of share options covering 51,000 Class A Ordinary Shares. The options have an exercise price of $3.62 per share and expire on June 17, 2036. Following this grant, she holds options on 51,000 shares directly.
The option award vests in twelve substantially equal monthly installments over one year starting June 17, 2026. Any remaining unvested portion will vest immediately before the next annual shareholder meeting after the grant date, subject to her continued service through each vesting date.
Zura Bio Ltd director Parvinder Thiara received a grant of share options covering 51,000 Class A Ordinary Shares. The options have an exercise price of $3.62 and expire on June 17, 2036. They vest in twelve roughly equal monthly installments starting June 17, 2026, with any remaining unvested portion vesting just before the next annual shareholder meeting, subject to continued service.
Zura Bio Ltd director Steven J. Schoch received a grant of stock options as compensation. The award covers 51,000 options to buy Class A Ordinary Shares at an exercise price of $3.62 per share, expiring on June 17, 2036. The option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026, with any remaining unvested portion vesting immediately before the next annual meeting of shareholders, subject to his continued service.
Zura Bio Ltd director Ajay Nirula received a grant of share options covering 51,000 Class A Ordinary Shares. The options have an exercise price of $3.62 per share and expire on June 17, 2036. They vest in twelve substantially equal monthly installments over one year starting June 17, 2026, with any remaining unvested portion vesting the day before the next annual shareholder meeting, subject to his continued service. No common shares were bought or sold; this filing reflects a compensation-related award.
Zura Bio Ltd director Amit Munshi received an option grant for 51,000 shares of Class A Ordinary Shares. The option has an exercise price of $3.62 per share and expires on June 17, 2036. It vests in twelve substantially equal monthly installments over one year starting June 17, 2026, with any remaining unvested portion vesting immediately before the next annual shareholder meeting, contingent on continued service.
Zura Bio Ltd director Mark Eisner received a grant of share options for 51,000 Class A Ordinary Shares. The options have an exercise price of $3.62 per share and expire on June 17, 2036. This is a compensation-related award, not an open-market purchase or sale.
The option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026, subject to his continued service. Any remaining unvested portion will vest on the day immediately before the next annual meeting of shareholders following the grant date. After this award, Eisner holds 51,000 options directly.
Zura Bio Ltd director Daniel J. Becker received a grant of 51,000 stock options on June 17, 2026. These options allow him to buy Class A Ordinary Shares at an exercise price of $3.62 per share and expire on June 17, 2036.
According to the terms, the award vests in twelve substantially equal monthly installments over one year starting June 17, 2026. Any remaining unvested portion will vest immediately before the next annual meeting of shareholders, as long as he continues in service through each vesting date.
Zura Bio Limited held its Annual General Meeting of Shareholders on June 17, 2026, where a quorum was present. Shareholders approved an amendment and restatement of the company’s 2023 Equity Incentive Plan, which became effective immediately upon approval.
All eight director nominees were elected to serve until the next annual general meeting or earlier departure. Shareholders also ratified the appointment of WithumSmith+Brown, PC as independent registered public accounting firm for the fiscal year ending December 31, 2026. Because the director slate, auditor ratification and equity plan proposals all received sufficient support, the contingency proposal to adjourn the meeting was not submitted for a vote.